Intimation of Investor Presentation - Q4/FY25
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech reported strong FY25 results with revenue of ₹481.3 crore, up 39% year-on-year, and Q4 revenue of ₹143.7 crore, up 40% YoY. EBITDA for FY25 surged 209% YoY to ₹121.6 crore, with margins expanding sharply to 26% from 12% in FY24. Profit after tax stood at ₹76.4 crore (versus a loss last year), translating to EPS of ₹26.35. The company reduced total debt by 17% to ₹109 crore, improving its debt-to-equity ratio from 0.46 to 0.30, while ROE rebounded to 23% from negative territory. Subsidiaries in Germany and the US showed strong growth, with the German arm turning profitable. The company also completed validation batches for new plant-based Vitamin D3 products (Vitadee Green) and a spray-dried variant.
This is a strong turnaround story for shareholders — profit margins nearly doubled, debt came down, and returns on equity swung from negative to 23%, all of which should be viewed positively by the market. Volume growth in human and animal nutrition plus new product launches suggest the recovery momentum could continue into FY26.